

Seoyoung C Kim, Scd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3601043/publications.pdf>

Version: 2024-02-01

194
papers

7,892
citations

53660

45
h-index

64668

79
g-index

200
all docs

200
docs citations

200
times ranked

10021
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. <i>Arthritis Care and Research</i> , 2010, 62, 170-180.	1.5	433
2	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis Care and Research</i> , 2020, 72, 744-760.	1.5	420
3	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis and Rheumatology</i> , 2020, 72, 879-895.	2.9	302
4	Active-comparator design and new-user design in observational studies. <i>Nature Reviews Rheumatology</i> , 2015, 11, 437-441.	3.5	225
5	Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1729-1737.	3.1	213
6	Validation of rheumatoid arthritis diagnoses in health care utilization data. <i>Arthritis Research and Therapy</i> , 2011, 13, R32.	1.6	184
7	Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1577-1585.	2.9	177
8	Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R154.	1.6	176
9	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1154-1164.	2.9	160
10	Tumor necrosis factor blockade and the risk of viral infection. <i>Nature Reviews Rheumatology</i> , 2010, 6, 165-174.	3.5	148
11	Patterns and predictors of persistent opioid use following hip or knee arthroplasty. <i>Osteoarthritis and Cartilage</i> , 2017, 25, 1399-1406.	0.6	139
12	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 456-464.	0.5	139
13	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 360, k119.	2.4	132
14	Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1674-1679.	0.5	113
15	Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 1600-1607.	1.5	108
16	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1360-1367.	0.5	108
17	Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. <i>Circulation</i> , 2018, 138, 1116-1126.	1.6	108
18	Fracture Risk After Bariatric Surgery: Roux-Y Gastric Bypass Versus Adjustable Gastric Banding. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1229-1236.	3.1	106

#	ARTICLE	IF	CITATIONS
19	Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study. <i>American Journal of Medicine</i> , 2015, 128, 519-526.e1.	0.6	98
20	Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0122646.	1.1	94
21	Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1536-1540.	3.1	90
22	Antibiotic Use in Children – A Cross-National Analysis of 6 Countries. <i>Journal of Pediatrics</i> , 2017, 182, 239-244.e1.	0.9	90
23	Gout. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 581-604.	0.8	83
24	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1968-1975.	0.5	82
25	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 123-139.	1.1	81
26	Fracture Risk After Initiation of Use of Canagliflozin. <i>Annals of Internal Medicine</i> , 2019, 170, 155.	2.0	81
27	Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 892-900.	2.9	81
28	Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 993-1001.	3.1	79
29	Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population-Based Cohort Study. <i>Arthritis Care and Research</i> , 2013, 65, 578-584.	1.5	79
30	Tofacitinib and risk of cardiovascular outcomes: results from the Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 798-804.	0.5	76
31	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 653.e7-653.e16.	0.6	75
32	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	1.5	73
33	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.5	72
34	Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. <i>Journal of the American College of Cardiology</i> , 2018, 71, 994-1004.	1.2	69
35	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. <i>Arthritis and Rheumatology</i> , 2017, 69, 387-397.	2.9	65
36	Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures. <i>JAMA Network Open</i> , 2018, 1, e180826.	2.8	64

#	ARTICLE	IF	CITATIONS
37	Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 789-796.	3.1	61
38	Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Non-Rheumatoid Arthritis Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 2004-2010.	2.9	57
39	Shift From Adalimumab Originator to Biosimilars in Denmark. <i>JAMA Internal Medicine</i> , 2020, 180, 902.	2.6	57
40	Identification of smoking using Medicare data - a validation study of claims-based algorithms. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 472-475.	0.9	55
41	Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	55
42	Bioequivalence of Biosimilar Tumor Necrosis Factor- α Inhibitors Compared With Their Reference Biologics. <i>Annals of Internal Medicine</i> , 2016, 165, 565.	2.0	52
43	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1528-1541.	2.0	52
44	Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1142.	2.0	51
45	Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. <i>BMJ: British Medical Journal</i> , 2017, 356, j895.	2.4	50
46	Risk of Incident Diabetes in Patients With Gout: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 273-280.	2.9	49
47	Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. <i>Cardiovascular Diabetology</i> , 2022, 21, 47.	2.7	49
48	Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. <i>JAMA Network Open</i> , 2019, 2, e198061.	2.8	48
49	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. <i>Circulation</i> , 2021, 143, 770-779.	1.6	47
50	Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. <i>Journal of Rheumatology</i> , 2018, 45, 1240-1248.	1.0	45
51	Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e84-e98.	2.2	45
52	Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 611-617.	3.1	44
53	Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 253-258.	1.6	43
54	Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. <i>JAMA Dermatology</i> , 2019, 155, 700.	2.0	43

#	ARTICLE	IF	CITATIONS
55	Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. <i>Rheumatology</i> , 2021, 60, 3689-3698.	0.9	43
56	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 222-228.	1.6	42
57	Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. <i>Rheumatology</i> , 2021, 61, 121-130.	0.9	41
58	Risk of incident atrial fibrillation in gout: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1473-1478.	0.5	40
59	Sociodemographic, Disease, Health System, and Contextual Factors Affecting the Initiation of Biologic Agents in Rheumatoid Arthritis: A Longitudinal Study. <i>Arthritis Care and Research</i> , 2014, 66, 980-989.	1.5	39
60	Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIC). <i>BMC Endocrine Disorders</i> , 2015, 15, 46.	0.9	39
61	Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 159.	1.6	37
62	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 399-405.	1.6	37
63	Fracture Risk After Roux-en-Y Gastric Bypass vs Adjustable Gastric Banding Among Medicare Beneficiaries. <i>JAMA Surgery</i> , 2019, 154, 746.	2.2	36
64	Changes in Use of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983-2009. <i>Arthritis Care and Research</i> , 2013, 65, 1529-1533.	1.5	35
65	Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. <i>Acta Diabetologica</i> , 2014, 51, 1015-1023.	1.2	35
66	Gout and Risk of Fracture in Women: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 422-428.	2.9	35
67	The risk of atrial fibrillation in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1091-1095.	0.5	34
68	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. <i>BMC Medical Research Methodology</i> , 2012, 12, 180.	1.4	33
69	Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT. <i>RMD Open</i> , 2018, 4, e000593.	1.8	33
70	Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 9-17.	1.5	33
71	An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. <i>PLoS ONE</i> , 2018, 13, e0193622.	1.1	33
72	Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2021, 4, e2130762.	2.8	32

#	ARTICLE	IF	CITATIONS
73	Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STARRA) Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1648-1659.	2.9	31
74	Bisphosphonates and risk of atrial fibrillation: a meta-analysis. <i>Arthritis Research and Therapy</i> , 2010, 12, R30.	1.6	30
75	No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. <i>Arthritis and Rheumatism</i> , 2012, 64, 3076-3082.	6.7	30
76	Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs. <i>American Journal of Medicine</i> , 2015, 128, 539.e7-539.e17.	0.6	30
77	Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 809-814.	0.5	30
78	Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212905.	0.5	29
79	Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. <i>Rheumatology</i> , 2019, 58, 2122-2129.	0.9	29
80	Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. <i>European Heart Journal</i> , 2021, 42, 4578-4588.	1.0	29
81	Disease-Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study. <i>Arthritis Care and Research</i> , 2015, 67, 457-466.	1.5	28
82	The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole. <i>Translational Psychiatry</i> , 2018, 8, 87.	2.4	28
83	Clinical Characteristics and Medication Uses Among Fibromyalgia Patients Newly Prescribed Amitriptyline, Duloxetine, Gabapentin, or Pregabalin. <i>Arthritis Care and Research</i> , 2013, 65, 1813-1819.	1.5	27
84	Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. <i>Arthritis and Rheumatology</i> , 2016, 68, 1183-1189.	2.9	27
85	Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. <i>JAMA Internal Medicine</i> , 2019, 179, 741.	2.6	27
86	Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 314-324.e16.	2.4	27
87	Association of Geography and Access to Health Care Providers With Long-Term Prescription Opioid Use in Medicare Patients With Severe Osteoarthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 712-721.	2.9	26
88	Comparative Fracture Risks Among United States Medicaid Enrollees With and Those Without Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1141-1146.	2.9	26
89	Gout and the Risk of Non-vertebral Fracture. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 230-236.	3.1	25
90	Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e027495.	0.8	25

#	ARTICLE	IF	CITATIONS
91	Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout. <i>Arthritis Care and Research</i> , 2013, 65, 2008-2014.	1.5	24
92	Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 42.	2.1	23
93	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. <i>Molecular Psychiatry</i> , 2021, 26, 1332-1345.	4.1	23
94	Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. <i>Diabetes Care</i> , 2021, 44, 2293-2301.	4.3	23
95	Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1792-1805.	1.5	22
96	Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1239-1244.	0.9	21
97	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , 2021, 157, 805.	2.0	21
98	Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 467-475.	0.9	21
99	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 300-311.	0.6	20
100	Validation of obesity-related diagnosis codes in claims data. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2623-2631.	2.2	20
101	Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2106-2113.	2.9	19
102	Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 401-408.	1.6	19
103	Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. <i>Arthritis and Rheumatology</i> , 2020, 72, 1036-1038.	2.9	19
104	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. <i>Journal of General Internal Medicine</i> , 2015, 30, 1633-1638.	1.3	18
105	Tumor Necrosis Factor- γ Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. <i>Epidemiology</i> , 2016, 27, 414-422.	1.2	18
106	Association between inflammation and systolic blood pressure in RA compared to patients without RA. <i>Arthritis Research and Therapy</i> , 2018, 20, 107.	1.6	18
107	Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis. <i>Journal of the American College of Cardiology</i> , 2022, 80, 36-46.	1.2	17
108	Relationships Between Driving Distance, Rheumatoid Arthritis Diagnosis, and Disease-Modifying Antirheumatic Drug Receipt. <i>Arthritis Care and Research</i> , 2014, 66, 1634-1643.	1.5	16

#	ARTICLE	IF	CITATIONS
109	Validation of claims-based algorithms to identify interstitial lung disease in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 592-597.	1.6	16
110	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2020, 156, 342.	2.0	16
111	Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia. <i>Arthritis Research and Therapy</i> , 2015, 17, 18.	1.6	15
112	Validation of claims-based algorithms for gout flares. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 820-826.	0.9	15
113	Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. <i>American Journal of Kidney Diseases</i> , 2018, 72, 178-187.	2.1	15
114	Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [¹⁸ F]DOPA PET and fMRI study. <i>Psychological Medicine</i> , 2019, 49, 2533-2542.	2.7	15
115	Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [¹⁸ F]DOPA and [¹¹ C]raclopride PET study in first-episode psychosis. <i>Molecular Psychiatry</i> , 2021, 26, 3476-3488.	4.1	15
116	Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score-Matched Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 52-60.	3.1	15
117	Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	15
118	Human Papillomavirus Vaccine Uptake among Individuals with Systemic Inflammatory Diseases. <i>PLoS ONE</i> , 2015, 10, e0117620.	1.1	14
119	Predictors of Stopping and Starting Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1152-1158.	1.5	13
120	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. <i>Arthritis Research and Therapy</i> , 2015, 17, 83.	1.6	13
121	Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. <i>Arthritis Care and Research</i> , 2018, 70, 791-796.	1.5	13
122	Assessment of body water distribution in patients with sepsis during fluid resuscitation using multi-frequency direct segmental bioelectrical impedance analysis. <i>Clinical Nutrition</i> , 2020, 39, 1826-1831.	2.3	13
123	Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning. <i>Journal of Rheumatology</i> , 2021, 48, 1364-1370.	1.0	13
124	Uptake of the First Biosimilar Infliximab since its Approval in South Korea. <i>Arthritis and Rheumatology</i> , 2015, 68, n/a-n/a.	2.9	12
125	Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. <i>Rheumatology</i> , 2018, 57, v26-v33.	0.9	12
126	Risk of Incident Type 2 Diabetes Mellitus Among Patients With Rheumatoid Arthritis: A Population-Based Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 1248-1256.	1.5	12

#	ARTICLE	IF	CITATIONS
127	Optimum Designs for Large Database Research in Musculoskeletal Pain Management. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 54-58.	1.4	12
128	Cardiovascular Safety of Urate Lowering Therapies. <i>Current Rheumatology Reports</i> , 2019, 21, 48.	2.1	11
129	Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. <i>Gut</i> , 2022, 71, 1781-1789.	6.1	11
130	Editorial: Safety of Immunosuppressive Drugs in Pregnant Women With Systemic Inflammatory Diseases. <i>Arthritis and Rheumatology</i> , 2014, 66, 246-249.	2.9	10
131	Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. <i>Arthritis Care and Research</i> , 2018, 70, 30-38.	1.5	10
132	Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa027.	0.3	10
133	Methodological Challenges in Conducting Large-Scale Real-World Data Analyses on Opioid Use in Musculoskeletal Disorders. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 10-14.	1.4	10
134	Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Drugs: A Cohort Study. <i>ACR Open Rheumatology</i> , 2020, 2, 222-231.	0.9	10
135	Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat. <i>Arthritis and Rheumatology</i> , 2021, 73, 542-543.	2.9	10
136	Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake?. <i>Expert Review of Vaccines</i> , 2014, 13, 931-934.	2.0	9
137	Fracture Risk After Initiation of Use of Canagliflozin. <i>Annals of Internal Medicine</i> , 2019, 171, 80.	2.0	9
138	Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 1383-1391.	1.5	9
139	Validation of claims-based algorithms for psoriatic arthritis. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 404-408.	0.9	9
140	Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. <i>Journal of the American Heart Association</i> , 2021, 10, e020045.	1.6	9
141	Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1242-1250.	1.6	9
142	Accuracy of identifying neutropenia diagnoses in outpatient claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 709-713.	0.9	8
143	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 757-769.	0.9	8
144	Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 770-777.	0.9	8

#	ARTICLE	IF	CITATIONS
145	Towards defining the safer use of opioids in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 71-72.	3.5	8
146	Association Between Inflammation, Incident Heart Failure, and Heart Failure Subtypes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2023, 75, 1036-1045.	1.5	8
147	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. <i>Arthritis and Rheumatology</i> , 2020, 72, 4-6.	2.9	7
148	Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development. <i>ACR Open Rheumatology</i> , 2020, 2, 65-73.	0.9	7
149	The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. <i>Arthritis Research and Therapy</i> , 2021, 23, 26.	1.6	7
150	Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs. <i>ACR Open Rheumatology</i> , 2021, 3, 531-539.	0.9	7
151	Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia. <i>Psychiatry Investigation</i> , 2020, 17, 1158-1165.	0.7	7
152	Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome. <i>BMC Rheumatology</i> , 2018, 2, 17.	0.6	6
153	A tool for empirical equipoise assessment in multigroup comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 934-941.	0.9	6
154	Increased Risk of Psychopathological Abnormalities in Subjects With Unilateral Hearing Loss: A Cross-Sectional Study. <i>Clinical and Experimental Otorhinolaryngology</i> , 2021, 14, 82-87.	1.1	6
155	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1427-1434.	0.9	6
156	Patterns of Bisphosphonates Utilization in Patients under Age 45 in a Large Cohort of Commercial Insurance Beneficiaries in the United States. <i>PLoS ONE</i> , 2015, 10, e0115091.	1.1	6
157	Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013-2017. <i>American Journal of Nephrology</i> , 2021, 52, 919-928.	1.4	6
158	Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIC Study. <i>Diabetes Therapy</i> , 2016, 7, 349-360.	1.2	5
159	Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	5
160	Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. <i>Journal of General Internal Medicine</i> , 2022, 37, 1917-1924.	1.3	5
161	Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 167-175.	0.9	5
162	Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. <i>Rheumatology</i> , 2021, 60, 3789-3798.	0.9	5

#	ARTICLE	IF	CITATIONS
163	Assessment of coronary vascular function with cardiac PET in relation to serum uric acid. PLoS ONE, 2018, 13, e0192788.	1.1	4
164	Identification of Acute Giant Cell Arteritis in Real-World Data Using Administrative Claims-Based Algorithms. ACR Open Rheumatology, 2021, 3, 72-78.	0.9	4
165	Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study. Drugs and Aging, 2020, 37, 311-320.	1.3	3
166	Validation of claims-based algorithms to identify patients with psoriasis. Pharmacoepidemiology and Drug Safety, 2021, 30, 868-874.	0.9	3
167	Behavioral and Clinical Factors Associated with Self-Reported Abnormal Papanicolaou Tests in Rheumatoid Arthritis. Journal of Women's Health, 2014, 23, 771-776.	1.5	2
168	Assessment for Perioperative Hyperglycemia Prior to Total Joint Replacement in Patients With and Without Diabetes. JAMA Network Open, 2019, 2, e1910589.	2.8	2
169	Risk of Diabetes Mellitus in Patients with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2020, 47, 1405-1408.	1.0	2
170	Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden. Rheumatology, 2021, 60, 2755-2764.	0.9	2
171	Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study. BMJ Open, 2020, 10, e041167.	0.8	2
172	Knee osteonecrosis incidence from two real-world data sources. Osteoarthritis and Cartilage Open, 2021, 3, 100169.	0.9	2
173	Risk of Non-Vertebral Fracture in Gout Compared to Rheumatoid Arthritis. Journal of Clinical Medicine, 2021, 10, 4655.	1.0	2
174	Comparative safety of nonsteroidal anti-inflammatory drugs. Nature Reviews Cardiology, 2011, 8, 193-195.	6.1	1
175	Potential confounding in colchicine and cardiovascular disease study. Annals of the Rheumatic Diseases, 2016, 75, e27-e27.	0.5	1
176	Response to: "Effects of colchicine on risk of cardiovascular events among patients with gout: as evidence accrues, is it time for a randomized trial?" by Giannopoulos and Deftereos. Annals of the Rheumatic Diseases, 2016, 75, e29-e29.	0.5	1
177	FRAILITY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES. Innovation in Aging, 2019, 3, S582-S582.	0.0	1
178	Development of a Medicare Claims-Based Model to Predict Persistent High-Dose Opioid Use After Total Knee Replacement. Arthritis Care and Research, 2022, 74, 1342-1348.	1.5	1
179	Temporal Trends in Prescribing of Bone-Directed Therapies in the United States, 2009-2020. Journal of the Endocrine Society, 2021, 5, A250-A250.	0.1	1
180	Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1106-1117.	0.5	1

#	ARTICLE	IF	CITATIONS
181	Cardiovascular and mortality risk with intravitreal vascular endothelial growth factor inhibitor in patients with diabetic retinopathy. <i>Ophthalmology Retina</i> , 2022, , .	1.2	1
182	Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006. <i>Arthritis Research and Therapy</i> , 2014, 16, A37.	1.6	0
183	Serious infection incidence rates in pediatric systemic lupus erythematosus according to medication use. <i>Arthritis Research and Therapy</i> , 2014, 16, A39.	1.6	0
184	Alendronate and Hip Fracture in Patients Using Glucocorticoids. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1711.	3.8	0
185	S156. FRONTO-STRIATAL FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE CAPACITY IN TREATMENT-RESPONSIVE AND REFRACTORY SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S386-S386.	2.3	0
186	Change in Cognitive Function after Antipsychotics Treatment : A Pilot Study of Long-Acting Injectable versus Oral Form. <i>Korean Journal of Schizophrenia Research</i> , 2018, 21, 74.	0.3	0
187	FRIO119â€¦PREDICTING REMISSION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS STARTING TOCILIZUMAB MONOTHERAPY: MODEL DERIVATION AND VALIDATION USING CONVENTIONAL REGRESSION AND MACHINE LEARNING. , 2019, , .		0
188	FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES. <i>Innovation in Aging</i> , 2019, 3, S582-S582.	0.0	0
189	S203. EFFECT OF LONG-ACTING INJECTIONS OF PALIPERIDONE PALMITATE ON CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA BASED ON ILLNESS DURATION. <i>Schizophrenia Bulletin</i> , 2020, 46, S115-S116.	2.3	0
190	Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study. <i>Psychiatry Investigation</i> , 2021, 18, 968-976.	0.7	0
191	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2022, 175, W4.	2.0	0
192	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2022, 175, W4-W5.	2.0	0
193	Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 836-845.	2.3	0
194	Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records. <i>BioDrugs</i> , 2022, 36, 521-535.	2.2	0